All filters
Videos
Leveraging Reverse Transcriptase 2020 | Laura Waters
Presented at:
Leveraging Reverse Transcriptase in HIV: Past, Present, and Future 2020
Videos
Leveraging Reverse Transcriptase 2020 | Jean-Michel Molina
Presented at:
Leveraging Reverse Transcriptase in HIV: Past, Present, and Future 2020
Videos
Leveraging Reverse Transcriptase 2020 | Chloe Orkin
Presented at:
Leveraging Reverse Transcriptase in HIV: Past, Present, and Future 2020
Videos
Leveraging Reverse Transcriptase 2020 | Martin Markowitz
Presented at:
Leveraging Reverse Transcriptase in HIV: Past, Present, and Future 2020
Videos
Leveraging Reverse Transcriptase 2020 | Daniel Kuritzkes
Presented at:
Leveraging Reverse Transcriptase in HIV: Past, Present, and Future 2020
Videos
Leveraging Reverse Transcriptase in HIV | Judith Currier
Presented at:
Leveraging Reverse Transcriptase in HIV: Past, Present, and Future 2020
Slidesets
Leveraging Reverse Transcriptase | Pozniak
Presented at:
Leveraging Reverse Transcriptase in HIV: Past, Present, and Future 2020
Slidesets
Leveraging Reverse Transcriptase 2020 | Waters
Presented at:
Leveraging Reverse Transcriptase in HIV: Past, Present, and Future 2020
Slidesets
Leveraging Reverse Transcriptase 2020 | Molina
Presented at:
Leveraging Reverse Transcriptase in HIV: Past, Present, and Future 2020
Slidesets
Leveraging Reverse Transcriptase 2020 | Orkin
Presented at:
Leveraging Reverse Transcriptase in HIV: Past, Present, and Future 2020
Slidesets
Leveraging Reverse Transcriptase 2020 | Markowitz
Presented at:
Leveraging Reverse Transcriptase in HIV: Past, Present, and Future 2020
Slidesets
Leveraging Reverse Transcriptase 2020 | Kuritzkes
Presented at:
Leveraging Reverse Transcriptase in HIV: Past, Present, and Future 2020
Slidesets
Leveraging Reverse Transcriptase 2020 | Currier
Presented at:
Leveraging Reverse Transcriptase in HIV: Past, Present, and Future 2020
Abstracts
Protein binding determination of second-line anti-tuberculosis drugs in vitro using an ultrafiltration technique
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Comparison of a Bayesian forecasting algorithm handling inter-occasion variability and a linear regression approach for dose individualization of rifampicin
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Mathematical modeling using in vitro checkerboard assay data: Clofazimine as a potentially synergistic anti-TB drug
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Levofloxacin urine kinetics and development of a colorimetric assay for therapeutic drug monitoring among people living with HIV and TB
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Optimal dose individualisation of rifampicin needs to account for between-occasion variability
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Population Pharmacokinetics and Model-Informed Precision Dosing of Isoniazid in Tuberculosis Patients
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Mechanistic modelling of time-to-positivity and colony-forming unit in tuberculosis patients on high-dose rifampicin to improve understanding of biomarker relation
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Drug effect of clofazimine on persistent mycobacteria explain an unexpected increase of bacterial load in patients
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Stratified dosage regimens from early bactericidal activity studies: an application to pretomanid
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
A PBPK modelling approach to simulate the rifampicin-moxifloxacin drug-drug interaction in TB patients
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019